Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gilbert

Showing results (731-740 of 869) with videos related to

Pageof 87
Sort By:
Scientific Reports|December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluationYunda Huang, Oleg Borisov, Jia Jin Kee, et al.
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Virology|November 27, 2009
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesMichael S Seaman, Holly Janes, Natalie Hawkins, et al.
Journal of the Neurological Sciences|October 22, 2019
Implication of the SH3TC2 gene in Charcot-Marie-Tooth disease associated with deafness and/or scoliosis: Illustration with four new pathogenic variantsJ Lerat, C Magdelaine, A Lunati, et al.
The New England Journal of Medicine|June 14, 2018
Effect of Dengue Serostatus on Dengue Vaccine Safety and EfficacySaranya Sridhar, Alexander Luedtke, Edith Langevin, et al.
Ebiomedicine|November 14, 2025
Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trialValentin Voillet, Janine van Duijn, Kanika Vanshylla, et al.
Cell|June 12, 2025
Neuropeptides specify and reprogram division of labor in the leafcutter ant Atta cephalotesMichael B Gilbert, Karl M Glastad, Maxxum Fioriti, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Vaccine|September 10, 2025
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trialDavid J Diemert, Daniel S Graciaa, Bo Zhang, et al.
Nature Communications|February 22, 2019
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccineSlim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, et al.
Pageof 87

Showing results (731-740 of 869) with videos related to

Sort By:
Pageof 87
Scientific Reports|December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluationYunda Huang, Oleg Borisov, Jia Jin Kee, et al.
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Virology|November 27, 2009
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesMichael S Seaman, Holly Janes, Natalie Hawkins, et al.
Journal of the Neurological Sciences|October 22, 2019
Implication of the SH3TC2 gene in Charcot-Marie-Tooth disease associated with deafness and/or scoliosis: Illustration with four new pathogenic variantsJ Lerat, C Magdelaine, A Lunati, et al.
The New England Journal of Medicine|June 14, 2018
Effect of Dengue Serostatus on Dengue Vaccine Safety and EfficacySaranya Sridhar, Alexander Luedtke, Edith Langevin, et al.
Ebiomedicine|November 14, 2025
Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trialValentin Voillet, Janine van Duijn, Kanika Vanshylla, et al.
Cell|June 12, 2025
Neuropeptides specify and reprogram division of labor in the leafcutter ant Atta cephalotesMichael B Gilbert, Karl M Glastad, Maxxum Fioriti, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Vaccine|September 10, 2025
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trialDavid J Diemert, Daniel S Graciaa, Bo Zhang, et al.
Nature Communications|February 22, 2019
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccineSlim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, et al.
Pageof 87